- Shares of nanotherapeutic concern Clene Inc. (CLNN) are down some 75% from its first trade as a public company back in December 2020.
- The company’s lead asset (CNM-Au8) flunked a Phase 2 ALS trial on primary and secondary endpoints but other exploratory data suggest potential for success in an ongoing Phase 3 study.
- With a theoretically paradigm-changing treatment approach pursuing three valuable CNS indications, the recent insider buying merited further investigation.
- A full investment analysis follows in the paragraphs below.
For further details see:
Clene Inc.: A First Take